InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
其他已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Discover the detailed record of transactions filed by Hogge Gary S., Officier. Insider active across 1 company, notably Lineage Cell Therapeutics, Inc.. Aggregated, 2 filings have been published. History available since 28 December 2021. The latest transaction was filed on 28 December 2021 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Hogge Gary S.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报2 总计
13,020 股Common Shares, no par valueSEC:0001493152-23-004895:0
185,000 股@ US$0.6919100.0% 占其流量Common Shares, no par valueSEC:0001493152-21-032897:0
2 条申报中的 2 条
About Hogge Gary S.
Gary S. Hogge is Senior Vice President of Clinical and Medical Affairs at Lineage Cell Therapeutics, Inc. He is responsible for the strategic direction of the company's clinical and medical initiatives. Hogge plays a key role in optimizing processes and improving clinical outcomes. His expertise in regenerative medicine is an asset for Lineage.
